Proteinase-activated receptor 2 (PAR-2) in gastrointestinal and pancreatic pathophysiology, inflammation and neoplasia.
Of all the body systems, the gastrointestinal (GI) tract is the most exposed to proteinases. Proteolytic activity must thus be tightly regulated in the face of diverse environmental challenges, because unrestrained or excessive proteolysis leads to pathological GI conditions. The protease-activated receptor-2 (PAR-2) is expressed in numerous cell types within the GI tract, suggesting both multiple functions and numerous modes of receptor activation. Although best known as a pancreatic digestive enzyme, trypsin has also been found in other tissues and various cancers. Of interest, trypsin and PAR-2 act together in an autocrine loop that promotes proliferation, invasion and metastasis in neoplasia through various mechanisms. Trypsin and PAR-2 seem to act both directly and indirectly through activation of other proteinase cascades, including metalloproteinases. PAR-2 activation can participate in inflammatory reactions, be protective to mucosal surfaces, send or inhibit nociceptive messages, modify gut motility or secretory functions, and stimulate cell proliferation and motility. Several studies point to a role for the PARs in disease processes of the GI tract and pancreas ranging from inflammatory bowel disease, symptoms associated with irritable bowel syndrome, pain in pancreatitis, development of colon and other GI cancers, and even infectious colitis. Proteinases should not only be considered from the traditional view as digestive or degradative enzymes in the gut, but additionally as signalling molecules that actively participate in the spectrum of physiology and diseased states of the GI tract.
Søreide
Kjetil
K
Department of Surgery, Stavanger University Hospital, Stavanger, Norway. ksoreide@mac.com
D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D049109:Cell Proliferation; D006801:Humans; D007249:Inflammation / Q000201:enzymology* / Q000473:pathology; D007410:Intestinal Diseases / Q000201:enzymology* / Q000473:pathology; D010182:Pancreatic Diseases / Q000201:enzymology* / Q000473:pathology; D044464:Receptor, PAR-2 / Q000378:metabolism*; D015398:Signal Transduction; D013272:Stomach Diseases / Q000201:enzymology* / Q000473:pathology
D015415:Biomarkers; D044464:Receptor, PAR-2